1. Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women
- Author
-
Larry T. Enderby, Holly Lassila, Christine K. O'Neil, Paula A. Witt-Enderby, Frank D'Amico, Judith L. Balk, and Mary P. Kotlarczyk
- Subjects
medicine.medical_specialty ,Bone density ,business.industry ,Osteoporosis ,Placebo-controlled study ,Physiology ,medicine.disease ,Placebo ,Bone resorption ,Bone remodeling ,Pittsburgh Sleep Quality Index ,Melatonin ,Endocrinology ,Internal medicine ,medicine ,business ,medicine.drug - Abstract
The purpose of this double-blind study was to assess the effects of nightly melatonin supplementation on bone health and quality of life in perimenopausal women. A total of 18 women (ages 45-54) were randomized to receive melatonin (3mg, p.o., n=13) or placebo (n=5) nightly for 6months. Bone density was measured by calcaneal ultrasound. Bone turnover marker (osteocalcin, OC for bone formation and NTX for bone resorption) levels were measured bimonthly in serum. Participants completed Menopause-Specific Quality of Life-Intervention (MENQOL) and Pittsburgh Sleep Quality Index (PSQI) questionnaires before and after treatment. Subjects also kept daily diaries recording menstrual cycling, well-being, and sleep patterns. The results from this study showed no significant change (6-month-baseline) in bone density, NTX, or OC between groups; however, the ratio of NTX:OC trended downward over time toward a ratio of 1:1 in the melatonin group. Melatonin had no effect on vasomotor, psychosocial, or sexual MENQOL domain scores; however, it did improve physical domain scores compared to placebo (mean change melatonin: -0.6 versus placebo: 0.1, P
- Published
- 2012
- Full Text
- View/download PDF